* Ocular Therapeutix(tm) and Regeneron enter into strategic
collaboration to develop sustained release formulation of
aflibercept for the treatment of wet AMD and other serious
retinal diseases
The post BRIEF-Ocular and Regeneron enter into strategic collaboration to develop sustained release formulation of aflibercept appeared first on NASDAQ.